Precision Wealth Strategies LLC Invests $956,000 in Boston Scientific Co.

Precision Wealth Strategies LLC Invests $956000 in Boston Scientific Co. (NYSE:BSX)

Precision Wealth Strategies LLC acquired 16,530 shares of Boston Scientific Co.'s stock, valued at approximately $956,000 during the 4th quarter.

Boston Scientific Corporation

Boston Scientific Co. Receives Consensus Target Price of $76.70 from Brokerages

Boston Scientific Co. (NYSE:BSX) Given Consensus Rating of "Moderate Buy" by Brokerages

Boston Scientific Co. is assessed with a consensus target price of $76.70 by brokerages, signaling a potential rise in stock value.

Parallel Advisors LLC Sells 335 Shares of Boston Scientific Co.

Parallel Advisors LLC Sells 335 Shares of Boston Scientific Co. (NYSE:BSX)

Parallel Advisors LLC decreased its holding in Boston Scientific Co. by 3.3%, owning 9,709 shares worth $561,000.

Boston Scientific Rises Yet Lags Behind Market

Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Boston Scientific Corporation (BSX) closed the trading day at $75.57, indicating a +0.76% change from the previous session's end, but trailed the S&P 500.

StockNews.com Downgrades Boston Scientific to Hold

StockNews.com Downgrades Boston Scientific (NYSE:BSX) to Hold

StockNews.com downgraded Boston Scientific (NYSE:BSX) to hold, reflecting a neutral market outlook for the company.

Goldman Sachs Initiates Coverage on Boston Scientific with a Buy Rating and $90.00 Price Target

Goldman Sachs lists upside catalysts for Boston Scientific, starts stock with buy

Goldman Sachs initiated coverage on Boston Scientific Corporation with a Buy rating and a price target of $90.00, expecting a multi-year period of launching new products to boost revenue.

Insider Trading Activity in Boston Scientific Corp. (BSX) Shares

Taking a look at what insiders are doing to gauge the Boston Scientific Corp. (BSX)'s direction – Knox Daily

Boston Scientific Corp. insiders, including Butcher Arthur C, Brennan Daniel J., and EVP and CFO, sold shares worth a total of $9,525,341 on May 28, 2024.

Boston Scientific Corp. Identified as Key Player in Growing Atrial Septal Occluder Devices Market

Atrial Septal Occluder Devices Market Size, Share and Outlook (2024-2031)

The global atrial septal occluder devices market is expected to reach a high CAGR during the forecast period 2024-2031, driven by the high prevalence of atrial septal defects. Boston Scientific Corp. is identified as one of the major key players in this market, which is shifting towards transcatheter device closure as a preferred treatment for secundum ASDs and patent foramen ovale.

Boston Scientific Corp. Shares Purchased by D.A. Davidson & CO.

Boston Scientific Co. (NYSE:BSX) Shares Purchased by D.A. Davidson & CO.

D.A. Davidson & CO. boosted its holdings in Boston Scientific Co. by 6.0% in the 4th quarter, acquiring 529 shares. Other investors, including Bruce G. Allen Investments LLC, Sachetta LLC, Motco, Venturi Wealth Management LLC, and Asset Dedication LLC, also increased their positions in Boston Scientific.

Bioelectric Medicine Market to Grow at 6.4% CAGR

Bioelectric Medicine Market to Grow at 6.4% CAGR, Driven by Rising Prevalence of Chronic Diseases

The global bioelectric medicine market is projected to reach USD 37.2 billion by 2032, growing at a CAGR of 6.4% from 2023 to 2032. Boston Scientific invested USD 1.6 billion in R&D in 2021, focusing on innovations in implantable and non-invasive electroceutical devices.

Boston Scientific is a multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. The company is known for developing innovative medical solutions that improve the health of patients around the world.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

COM:BOSTONSCIENTIFIC

Boston Scientific Corporation

Last Close

86.88

08/11 21:00

Market Cap

113.37B

Beta: -

Volume Today

3.74M

Avg: -

Analysis Not Available